Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr57.70|
|52 Week High||kr47.20|
|52 Week Low||kr69.70|
|1 Month Change||7.05%|
|3 Month Change||2.12%|
|1 Year Change||-16.01%|
|3 Year Change||95.93%|
|5 Year Change||66.76%|
|Change since IPO||-97.76%|
Recent News & Updates
Karo Pharma (STO:KARO) Has No Shortage Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is Karo Pharma (STO:KARO) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|KARO||SE Pharmaceuticals||SE Market|
Return vs Industry: KARO underperformed the Swedish Pharmaceuticals industry which returned -3.2% over the past year.
Return vs Market: KARO underperformed the Swedish Market which returned 33.3% over the past year.
Stable Share Price: KARO is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: KARO's weekly volatility (4%) has been stable over the past year.
About the Company
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, rest of Europe, the United States, and internationally. It offers dermatology products under the Decubal, Fungobase, indy beauty, Lucobase, Mildison, OLIVA, PoxClin, and PROPYLESS brands; intimate care products under the HemoClin, Multi-Gyn, Multi-Mam, Pevaryl, Scheriproct, and Selexid brand names; and foot care products under the CCS, Cortimyk, Footner, Nailner, Pevaryl, and wortie brands. The company also provides pain, cough, and cold products under the Bronkyl, Dolerin, Ibux, Mollipect, Nazamer, nozoil, Paracet, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, and Kaleorid brands; and wellness products under the Flux, Allévo, Dosett, Dax, antibac, BAMSE, Betavivo, and Lactocare brands.
Karo Pharma Fundamentals Summary
|KARO fundamental statistics|
Is KARO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KARO income statement (TTM)|
|Cost of Revenue||kr1.26b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 28, 2021
|Earnings per share (EPS)||0.0078|
|Net Profit Margin||0.061%|
How did KARO perform over the long term?See historical performance and comparison
Is Karo Pharma undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KARO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KARO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KARO is poor value based on its PE Ratio (7426x) compared to the Swedish Pharmaceuticals industry average (157.1x).
PE vs Market: KARO is poor value based on its PE Ratio (7426x) compared to the Swedish market (23.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KARO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KARO is good value based on its PB Ratio (2.2x) compared to the SE Pharmaceuticals industry average (3.7x).
How is Karo Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Karo Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Karo Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KARO has a large one-off loss of SEK60.8M impacting its June 30 2021 financial results.
Growing Profit Margin: KARO's current net profit margins (0.06%) are lower than last year (3.4%).
Past Earnings Growth Analysis
Earnings Trend: KARO has become profitable over the past 5 years, growing earnings by -2.3% per year.
Accelerating Growth: KARO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: KARO had negative earnings growth (-98%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-43.2%).
Return on Equity
High ROE: KARO's Return on Equity (0.04%) is considered low.
How is Karo Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: KARO's short term assets (SEK1.9B) do not cover its short term liabilities (SEK5.8B).
Long Term Liabilities: KARO's short term assets (SEK1.9B) exceed its long term liabilities (SEK1.6B).
Debt to Equity History and Analysis
Debt Level: KARO's debt to equity ratio (108.1%) is considered high.
Reducing Debt: Insufficient data to determine if KARO's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: KARO's debt is not well covered by operating cash flow (5.4%).
Interest Coverage: KARO's interest payments on its debt are not well covered by EBIT (1.2x coverage).
What is Karo Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KARO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KARO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KARO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KARO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: KARO is not paying a notable dividend for the Swedish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KARO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Christoffer Lorenzen (46 yo)
Mr. Christoffer Lorenzen has been the Chief Executive Officer of Karo Pharma AB since July 1, 2019. Mr. Lorenzen was an Executive Vice President of Food Cultures & Enzymes at Chr. Hansen Holding A/S from A...
CEO Compensation Analysis
Compensation vs Market: Christoffer's total compensation ($USD1.39M) is above average for companies of similar size in the Swedish market ($USD802.45K).
Compensation vs Earnings: Christoffer's compensation has been consistent with company performance over the past year.
Experienced Management: KARO's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: KARO's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Karo Pharma AB (publ)'s employee growth, exchange listings and data sources
- Name: Karo Pharma AB (publ)
- Ticker: KARO
- Exchange: OM
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr12.984b
- Shares outstanding: 225.03m
- Website: https://www.karopharma.com
Number of Employees
- Karo Pharma AB (publ)
- Klara Norra Kyrkogata 33
- Stockholm County
- 111 22
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 20:55|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.